Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on December 29, 2025. The filing discloses a strategic decision to discontinue the RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). The company intends to reallocate resources to the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and strategic realignment rather than financial performance.
Material Changes and Clinical Data
The primary material change is the cessation of enrollment in the RAMP 203 trial. Interim data as of November 26, 2025, for 66 evaluable patients treated at the recommended Phase 2 dose included:
- Doublet Combination (Avutometinib + Sotorasib):
- Treatment-naïve (30 patients): Overall Response Rate (ORR) of 40% (12/30); Median Progression-Free Survival (PFS) of 11.1 months.
- Previously treated (21 patients): ORR of 9.5% (2/21); Median PFS of 3.7 months.
- Triplet Combination (Avutometinib + Sotorasib + Defactinib):
- Treatment-naïve (4 evaluable): ORR of 50% (2/4); Median PFS could not be determined.
- Previously treated (11 evaluable): 36% (4/11) showed greater than 30% tumor reduction; Median PFS of 3.6 months.
- Safety: No dose-limiting toxicities were observed. Common adverse events included nausea (56.8%), diarrhea (52.7%), and fatigue (45.9%).
Outlook, Risks, and Management Commentary
Management stated the decision to discontinue RAMP 203 reflects the evolving treatment landscape for KRAS G12C inhibitors and a strategic prioritization of programs with the greatest potential impact. Patients currently enrolled may continue treatment at the investigator's discretion. The company will focus on VS-7375 for advanced NSCLC and other solid tumors. The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties that could cause actual results to differ from expectations.
Key Facts for Investor Verification
- Confirm the specific timeline and resource allocation plan for the VS-7375 clinical development program.
- Verify the financial impact of discontinuing the RAMP 203 trial on the company's cash burn rate and runway.
- Review the competitive landscape for KRAS G12C inhibitors to understand the strategic rationale for the pivot.
- Monitor upcoming data presentations for VS-7375 to assess the viability of the new strategic focus.